DOCSLIB.ORG

FULL NAME Contact Company ID Email 3M Company Suzanne Danielson CC0013 [email protected] 3M Unitek Corporation Vincent Martinez CC0361 [email protected] A-Dec, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FULL NAME Contact Company ID Email 3M Company Suzanne Danielson CC0013 Smdanielson@Mmm.Com 3M Unitek Corporation Vincent Martinez CC0361 Vcmartinez@Mmm.Com A-Dec, Inc FULL_NAME Contact Company_ID Email 3M Company Suzanne Danielson CC0013 [email protected] 3M Unitek Corporation Vincent Martinez CC0361 [email protected] A-dec, Inc. Anh Vo CC0721 [email protected] ARIAD Pharmaceuticals Chad A. Morin CC0645 [email protected] ATS Medical Astrid Berthe CC0414 [email protected] AbbVie, Inc. Lynne Inman CC0690 [email protected] Abbott Laboratories Joanne Lee CC0017 [email protected] Abiomed Inc. Stephen McEvoy CC0038 [email protected] Abraxis Bioscience Inc. Charles Kim CC0039 [email protected] Acadia Pharmaceuticals, Inc. Ryan Brown CC0830 [email protected] AccessClosure, Inc. John Buckley CC0541 [email protected] Acclarent Inc. Susan Clarke CC0040 [email protected] Accuray Incorporated Alaleh Nouri CC0692 [email protected] Acorda Therapeutics, Inc. Naresha Moore CC0041 [email protected] Actavis, PLC Alicia Riegle CC0376 [email protected] Actelion Pharmaceuticals U.S., Inc. Nimit Gajera CC0042 [email protected] Actient Pharmaceuticals LLC Steve Griffin CC0617 steve.griffin@actientpharma. Acumed Llc Tony Damas CC0026 [email protected] Adolor Corporation Elizabeth Jobes CC0043 [email protected] Advanced BioHealing, Inc. Bill Benvenuto CC0413 [email protected] Advanced Bionics Darci Teobaldi CC0044 darci.teobaldi@advancedbioni Advanced Orthopaedic Solutions Inc. Anna Hwang CC0655 [email protected] Advandx Inc. Emad Lababidi CC0023 [email protected] Aegerion Pharmaceuticals, Inc. Deidre Arnold CC0647 [email protected] Aesculap Implant Systems, Inc. Karen Smickley CC0034 karen.smickley@aesculap. Aesculap Inc. Karen Smickley CC0033 karen.smickley@aesculap. Afaxys, Inc. Nancy Duncan CC0657 [email protected] Agency For Medical Innovations Andrew Bendheim CC0372 [email protected] Agency for Medical Innovations Inc. Andrew Bendheim CC0515 [email protected] Agilent Technologies, Inc. Tania Saison CC0836 [email protected] Akorn, Inc. Sara Ames CC0726 [email protected] Akrimax Pharmaceuticals, LLC Keith S. Rotenberg, CC0741 [email protected] Alcon Laboratories, Inc. Barb Barr CC0045 [email protected] Alcresta Pharmaceuticals, Inc. Regina Wagner CC0812 [email protected] Alere Inc. Christine Meyers CC0205 [email protected] Alexion Pharmaceuticals, Inc. Edward Miller CC0028 [email protected] Algeta US, LLC Brian Adams CC0713 [email protected] Align Technology Inc. Scott Meggs CC0036 [email protected] Alimed, Inc. Brian Thomas CC0027 [email protected] Alimera Sciences, Inc. Jeff Burris CC0776 jeff.burris@alimerasciences. Alkermes Jodiann Lindsey CC0378 Jodi.Lindsey@Alkermes. Allergan, Inc. Alicia Riegle CC0046 [email protected] Allesee Orthodontic Appliances Inc. Gina Nese CC0669 [email protected] Alliqua BioMedical, Inc. Brian Posner CC0768 [email protected] Allos Therapeutics, Inc. Suzanne Brackley CC0416 [email protected] Alphatec Spine Sondra Boddy CC0529 [email protected] Altatec GMBH Raphael Brausch CC0524 [email protected] Amag Pharmaceuticals Inc. 1100 Winter St. CC0047 [email protected] Amarin Pharma Patricia Reynolds CC0679 patricia.reynolds@amarincorp. American Medical Systems, Inc. Francisco Rivas CC0048 [email protected] Ameridose, LLC Gregory A. Conigliaro CC0564 [email protected] Amgen Inc. Kathleen Hirose CC0367 [email protected] Amylin Pharmaceuticals, Inc. Ernie Hernandez CC0050 [email protected] Anacor Pharmaceuticals, Inc. Ryan T. Sullivan CC0743 [email protected] Analogic Corporation Joyce Kilroy CC0051 [email protected] Angelini Labopharm LLC Philippe Befferal CC0551 [email protected] Angio Dynamics, Inc. S. Michael Sharp CC0030 [email protected] Animas Corporation Denise Ragland CC0370 [email protected] Antares Pharma, Inc. Jennifer Evans Stacey CC0780 [email protected] Apatech, Inc. John Mattern CC0052 [email protected] Aperio Technologies, Inc. Patrick Yount CC0508 [email protected] Aphrodite Women's Health Susan Thompson CC0803 [email protected] ApoPharma USA Inc. Elizabeth Gill CC0618 [email protected] Apollo Endosurgery Inc. Lacey Daugherty CC0786 lacey.daugherty@apolloendo. Applied Medical Resources Corporati Hasan Alghadban CC0053 [email protected] Aptalis Pharma US, Inc. Robert Brown CC0610 [email protected] Aptevo Therapeutics Inc. Shawute Mitchell CC0859 [email protected] Aqua Pharmaceuticals, LLC Michael Doyle CC0792 [email protected] Arbor Pharmaceuticals, Inc. Leslie Zacks CC0630 [email protected] Argon Medical Devices, Inc. Sharon Mcnally CC0407 [email protected] Aribex Inc. Gina Nese CC0675 gina.nese@kavokerrgroup. Arkray America, Inc. Christopher Koshire CC0757 [email protected] Arthrex, Inc. Peggy Cooley CC0055 [email protected] ArthroCare Corp. Melinda Kielich CC0425 [email protected] Arthrosurface Inc. Shelly Scorpio CC0031 [email protected] Ascend Therapeutics Donna Shiroma CC0608 [email protected] Ascensia Diabetes Care US Inc. Andrei Trifonov- CC0861 andrei.trifonovserbinov@ascen Ascent Healthcare Solutions Tim Einwechter CC0056 [email protected] Aspect Medical Systems Christine Vozella CC0058 [email protected] Aspen Surgical Products Yinka Owolabi, CC0389 [email protected] Associates Of Cape Cod, Inc. AJ Meuse CC0057 [email protected] Astellas Pharmaceutical Us, Inc. Shelley Kuehneman CC0032 shelley.kuehneman@astellas. Astra Tech, Inc. Franklin Uyleman CC0059 Franklin.Uyleman@dentsply. Astrazeneca Pharmaceuticals Amy Haines CC0060 amy.haines@astrazeneca. Astute Medical, Inc. 3550 General Atomics Ct CC0762 [email protected] Atos Medical Inc Ruben Cardenas CC0371 Ruben.Cardenas@Atosmedical AtriCure, Inc. Christina Garcia CC0597 [email protected] Atrium Medical Corp. Gary Sufat CC0061 [email protected] Augmenix, Inc. Chelsea Reinhold CC0797 [email protected] Aurora Imaging Technology Michael Traister CC0062 [email protected] Auxilium Pharmaceuticals, Inc. Mike Saraceno CC0035 [email protected] Avanir Pharmaceuticals, Inc. Joanna Moore CC0582 [email protected] Avinger, Inc. Dan George CC0668 [email protected] B. Braun Interventional Systems Inc. Teresa Redline CC0075 [email protected] B. Braun Medical Inc. Teresa Redline CC0076 [email protected] BD RX Inc. Danielle Gallo CC0696 [email protected] BG Medicine Stacie Rader CC0691 [email protected] BMT Management, LLC Daniela Dieguez CC0599 [email protected] BTG International, Inc. Michele Turpening CC0623 [email protected] Baxalta U.S. Inc. Jennie Orrico CC0821 [email protected] Baxano Surgical Stephanie Fitts CC0339 [email protected] Baxano, Inc. Edward Sinclair CC0078 [email protected] Baxter Healthcare Corporation Denise Johnson CC0071 [email protected] Bayer Healthcare Llc Lawrence Platkin CC0079 [email protected] Beckman Coulter Tania Saison-Dodd CC0066 [email protected] Becton Dickinson And Company Danielle Gallo CC0070 [email protected] Belmont Instrument Corporation 780 Boston Rd CC0080 [email protected] Ben Venue Laboratories, Inc. Marcus Beasley CC0621 marcus.beasley@boehringer- Benvenue Medical Inc. Kaily Truong CC0752 [email protected] Bio-Rad Laboratories, Inc. Vicki Davidson CC0709 [email protected] BioBehavioral Diagnostics Teresa Lipcsey CC0503 [email protected] BioDelivery Sciences International Ernest DePaolantoni CC0761 [email protected] BioHorizons Implant Systems, Inc. David Dutil CC0531 [email protected] BioMarin Pharmaceutical Kim Carneal CC0527 [email protected] BioMerieux, Inc. Lori Russell CC0504 [email protected] Biofrontera Inc. Monica Tamborini CC0828 m.tamborini@biofrontera. Biogen MA Inc Scheivon Jarrett CC0082 [email protected] Bioness Inc Kim Tompkins CC0069 [email protected] Biosense Webster Tony Marshall CC0083 [email protected] Biotest Pharmaceuticals Corp. Donna Quinn CC0084 [email protected] Biotronik, Inc. Jon Brumbaugh CC0068 jon.brumbaugh@biotronik. Bioventus LLC Denice Denzin CC0649 denice.denzin@bioventusglobal Boehringer Ingelheim Pharmaceutical Sunitha Ramamurthy CC0085 sunitha.ramamurthy@Boehringe Bone Support Ab Carin Thorell CC0086 carin.nilson-thorell@bonesupport. Boston Scientific Corporation Jessica Pill CC0087 [email protected] Braeburn Pharmaceuticals Reed Brady CC0854 [email protected] Brainlab, Inc. Paul Neil CC0530 [email protected] Braintree Laboratories, Inc. Braintree Laboratories, CC0502 [email protected] Breg, Inc. Breg Inc CC0639 [email protected] Bristol-Myers Squibb Company Blake Bolinger CC0088 [email protected] Broncus Technologies, Inc. Gary Kaplan CC0543 [email protected] C. R. Bard, Inc. Brian J. Leddin CC0104 [email protected] CNS Therapeutics, Inc. Scott Bronson CC0552 [email protected] CSA Medical William Floyd CC0693 [email protected] Cadence Pharmaceuticals, Inc. Cheryl Toland CC0574 [email protected] Calypso Medical Technologies, Inc. Peter Buck CC0093 [email protected] Cambridge Heart Inc. Vincenzo Licausi CC0380 [email protected] Candela Corporation Laura Howes CC0105 laura.howes@candelalaser. Cantel Medical Corp. Avi Spira CC0734 [email protected] Cardiac Assist, Inc. John Marous CC0107 [email protected] Cardiac Science Michael Matysik CC0373 [email protected] Cardinal Health
Load more

Recommended publications
  • Alkermes Public Limited Company
    ALKERMES PUBLIC LIMITED COMPANY Directors’ Report and Consolidated Financial Statements For the Year Ended March 31, 2013 ALKERMES PLC Table of Contents Page Directors’ Report .......................................................... 2 Statement of Directors’ Responsibilities .......................................... 56 Independent Auditors’ Report—Group ........................................... 57 Consolidated Profit and Loss Account ........................................... 59 Consolidated Statement of Comprehensive Income (Loss) ............................. 60 Consolidated Balance Sheet ................................................... 61 Consolidated Statement of Cash Flows ........................................... 63 Consolidated Reconciliation of Shareholders’ Funds ................................. 62 Notes to the Consolidated Financial Statements .................................... 64 Independent Auditors’ Report—Company ......................................... 111 Company Balance Sheet ..................................................... 113 Notes to the Company Financial Statements ....................................... 114 1 DIRECTORS’ REPORT For the Year Ended March 31, 2013 The directors present their report and audited consolidated financial statements for the fiscal year ended March 31, 2013. The directors have elected to prepare the consolidated financial statements in accordance with section 1 of the Companies (Miscellaneous Provisions) Act, 2009, which provides that a true and fair view of the state of
    [Show full text]
  • From the Academy
    FROM THE ACADEMY Joint American Academy of DermatologyeNational Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy Craig A. Elmets, MD (Co-Chair),a HenryW.Lim,MD,b Benjamin Stoff, MD, MA,c Cody Connor, MD,a Kelly M. Cordoro, MD,d Mark Lebwohl, MD,e AprilW.Armstrong,MD,MPH,f Dawn M. R. Davis, MD,g Boni E. Elewski, MD,a Joel M. Gelfand, MD, MSCE,h Kenneth B. Gordon, MD,i AliceB.Gottlieb,MD,PhD,j Daniel H. Kaplan, MD, PhD,k Arthur Kavanaugh, MD,l Matthew Kiselica, BA/BS,m Dario Kivelevitch, MD,n Neil J. Korman, MD, PhD,o Daniela Kroshinsky, MD, MPH,p Craig L. Leonardi, MD,q Jason Lichten, MD,m NehalN.Mehta,MD,MSCE,r Amy S. Paller, MD,s Sylvia L. Parra, MD,t Arun L. Pathy, MD,u Elizabeth A. Farley Prater, MD,v Reena N. Rupani, MD,e Michael Siegel, PhD,m BruceE.Strober,MD,PhD,w,x Emily B. Wong, MD,y Jashin J. Wu, MD,z Vidhya Hariharan, PhD,aa and Alan Menter, MD (Co-Chair)n Birmingham, Alabama; Detroit, Michigan; Atlanta, Georgia; San Francisco, Los Angeles, San Diego, and Irvine, California; New York, New York; Rochester, Minnesota; Philadelphia and Pittsburgh, Pennsylva- nia; Milwaukee, Wisconsin; Portland, Oregon; Dallas and San Antonio, Texas; Cleveland, Ohio; Boston, Massachusetts; St. Louis, Missouri; Bethesda, Maryland; Chicago and Rosemont, Illinois; Sumter, South Carolina; Centennial, Colorado; Oklahoma City, Oklahoma; Farmington, Connecticut; and Waterloo, Ontario, Canada Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 3.2% of the world’s population.
    [Show full text]
  • In Re: Alkermes Securities Litigation 03-CV-12091-Consolidated
    Case 1:03-cv-12091-RCL Document 39 Filed 07/12/2004 Page 1 of 49 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS In re ALKERMES SECURITIES ) Master Docket No. 03-CV-12091-RCL LITIGATION ) ) CLASS ACTION This Document Relates To: ) ) ALL ACTIONS. ) ) ) CONSOLIDATED COMPLAINT FOR VIOLATION OF THE FEDERAL SECURITIES LAWS Case 1:03-cv-12091-RCL Document 39 Filed 07/12/2004 Page 2 of 49 SUMMARY AND OVERVIEW 1. This is a securities class action on behalf of all purchasers of the common stock of Alkermes, Inc. (“Alkermes” or the “Company”) between April 22, 1999 and July 1, 2002 (the “Class Period”), against Alkermes and certain of its officers and directors for violations of the Securities Exchange Act of 1934 (the “Exchange Act”). 2. Alkermes is a biopharmaceutical company focused on the development of controlled- release drug delivery technologies and their application to existing or new drug therapies. Among the drug delivery technologies defendants seek to develop are sustained-release systems based on biodegradable polymeric microspheres, including those based on Medisorb polymers. 3. In 1996, Alkermes entered into an agreement with JPI Pharmaceutical International (“Janssen”), an affiliate of pharmaceutical giant Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (“Johnson & Johnson”), to develop an injectable form of the schizophrenic drug Risperdal, based upon the Medisorb polymer technology, called Risperdal Consta. Janssen has marketed the oral form of Risperdal since 1993, with sales of $2.3 billion in 2003. According to a December 12, 2001 report by analysts Thomas Weisel Partners, LLC (“Thomas Weisel”), during the Class Period, oral Risperdal was the most prescribed drug in the $5.3 billion atypical antipsychotic market.
    [Show full text]
  • Annual Report on Annual Reports 2016
    ANNUAL REPORT ON ANNUAL REPORTS 2016 TOP 400 ANNUAL REPORTS WHO RANKS WHERE? 100 ANNUALS IN BRIEF BEST REPORTING PRACTICES Company Value > Report Value Annual Report on Annual Reports 2016 Contents Report rating scale 3 Top 400 annual reports 4 Who ranks where? 25 From ABB to ZTE 100 annuals in brief 58 From Abbott to Yamaha How important is the annual report today? 92 Views from Cecilia Ketels, Kellie Friery, Renee Carter, David Robinson, Kaevan Gazdar, Elena Moskvina, Thomas Rosenmayr, Rob Stangroom, Andrey Kozhevnikov, Ana Santamarina, Katie Holcomb, Ananda Jagoda Best practices on key report attibutes 100 Strategy, message, investor information, risks, style, online… How we make it 121 How is your report doing? The report scan 127 The report rating panel 128 Robert Berick, Susan Blesener, Renee Carter, Vero Escarmelle, Helena Fournial, Kaevan Gazdar, Mike Guillaume, Pradip Seth, Eva Wolosiuk Making reports pay off 133 e.com – ReportWatch 135 2 Report rating scale A+ ééééé First-rate A éééé(é) Excellent A- éééé Very good B+ ééé(é) Sound B ééé Average B- éé(é) Uneven C+ éé Common C é(é) Substandard C- é Poor D (é) Uncompetitive 3 Top 400 annual reports AkzoNobel (No. 1) Electrolux (No. 2 ) SCA (No. 3) Volvo (No. 4) 4 Report rank Company Country Report rating Compare 1 AKZONOBEL Netherlands A+ DUPONT 2 ELECTROLUX Sweden A+ WHIRLPOOL 3 SCA Sweden A+ KIMBERLY-CLARK 4 VOLVO Sweden A+ DAIMLER 5 POTASHCORP Canada A+ AGRIUM 6 ATLAS COPCO Sweden A SANDVIK 7 STORA ENSO Finland A UPM 8 BOLIDEN Sweden A GLENCORE 9 WIENERBERGER Austria A BORAL 10
    [Show full text]
  • 2012 Financial Markets Preview Living Creatively
    REPRINT FROM JANUARY 2, 2012 BioCentury ™ THE BERNSTEIN REPORT ON BIOBUSINESS Article Reprint • Page 1 of 8 2012 Financial Markets Preview Living creatively By Stacy Lawrence “As the capital markets Viren Mehta of Mehta Partners. “Many Senior Writer companies don’t have any option but to For small, early stage biotech compa- continue to be difficult, raise at lower valuations.” nies, 2012 could be the year of living traditional investors are able He added: “Many companies are not creatively. able to defer any longer. The moment Although public biotechs raised more to extract terms that are comes for many companies when they funds last year than ever before, the vast have to swallow hard and accept painful majority of the money was debt financing more and more onerous.” dilution.” by established companies with marketed products. Thus while the overall numbers Todd Wyche, Brinson Patrick look good and are likely to continue to do Cash on hand so, precommercial companies will have to large and mid-cap companies (see “The Market volatility and macroeconomic get creative with their financings. 1% Effect,” page 2). risk had most buysiders sitting on the Many of these companies avoided rais- In 2011, public biotechs raised $43 sidelines through the back half of 2011. ing money in 2011 because they didn’t billion, easily eclipsing the record $33.1 Bankers are hopeful that this year will be like the valuations, but Wall Streeters say billion in 2000. But debt accounted for more stable, in which case investors might they are now running out of cash. As a 82% of the total dollars raised, compared be willing to support more deal flow dur- result, they will have to use the tricks at to only 19% in 2000 (see “Debt Domi- ing 1H12 (see “Fear Factor,” page 5).
    [Show full text]
  • FTSE Japan ESG Low Carbon Select
    2 FTSE Russell Publications 19 August 2021 FTSE Japan ESG Low Carbon Select Indicative Index Weight Data as at Closing on 30 June 2021 Constituent Index weight (%) Country Constituent Index weight (%) Country Constituent Index weight (%) Country ABC-Mart 0.01 JAPAN Ebara 0.17 JAPAN JFE Holdings 0.04 JAPAN Acom 0.02 JAPAN Eisai 1.03 JAPAN JGC Corp 0.02 JAPAN Activia Properties 0.01 JAPAN Eneos Holdings 0.05 JAPAN JSR Corp 0.11 JAPAN Advance Residence Investment 0.01 JAPAN Ezaki Glico 0.01 JAPAN JTEKT 0.07 JAPAN Advantest Corp 0.53 JAPAN Fancl Corp 0.03 JAPAN Justsystems 0.01 JAPAN Aeon 0.61 JAPAN Fanuc 0.87 JAPAN Kagome 0.02 JAPAN AEON Financial Service 0.01 JAPAN Fast Retailing 3.13 JAPAN Kajima Corp 0.1 JAPAN Aeon Mall 0.01 JAPAN FP Corporation 0.04 JAPAN Kakaku.com Inc. 0.05 JAPAN AGC 0.06 JAPAN Fuji Electric 0.18 JAPAN Kaken Pharmaceutical 0.01 JAPAN Aica Kogyo 0.07 JAPAN Fuji Oil Holdings 0.01 JAPAN Kamigumi 0.01 JAPAN Ain Pharmaciez <0.005 JAPAN FUJIFILM Holdings 1.05 JAPAN Kaneka Corp 0.01 JAPAN Air Water 0.01 JAPAN Fujitsu 2.04 JAPAN Kansai Paint 0.05 JAPAN Aisin Seiki Co 0.31 JAPAN Fujitsu General 0.01 JAPAN Kao 1.38 JAPAN Ajinomoto Co 0.27 JAPAN Fukuoka Financial Group 0.01 JAPAN KDDI Corp 2.22 JAPAN Alfresa Holdings 0.01 JAPAN Fukuyama Transporting 0.01 JAPAN Keihan Holdings 0.02 JAPAN Alps Alpine 0.04 JAPAN Furukawa Electric 0.03 JAPAN Keikyu Corporation 0.02 JAPAN Amada 0.01 JAPAN Fuyo General Lease 0.08 JAPAN Keio Corp 0.04 JAPAN Amano Corp 0.01 JAPAN GLP J-REIT 0.02 JAPAN Keisei Electric Railway 0.03 JAPAN ANA Holdings 0.02 JAPAN GMO Internet 0.01 JAPAN Kenedix Office Investment Corporation 0.01 JAPAN Anritsu 0.15 JAPAN GMO Payment Gateway 0.01 JAPAN KEWPIE Corporation 0.03 JAPAN Aozora Bank 0.02 JAPAN Goldwin 0.01 JAPAN Keyence Corp 0.42 JAPAN As One 0.01 JAPAN GS Yuasa Corp 0.03 JAPAN Kikkoman 0.25 JAPAN Asahi Group Holdings 0.5 JAPAN GungHo Online Entertainment 0.01 JAPAN Kinden <0.005 JAPAN Asahi Intecc 0.01 JAPAN Gunma Bank 0.01 JAPAN Kintetsu 0.03 JAPAN Asahi Kasei Corporation 0.26 JAPAN H.U.
    [Show full text]
  • March 31, 2021
    Units Cost Market Value US Equity Index Fund US Equities 95.82% Domestic Common Stocks 10X GENOMICS INC 126 10,868 24,673 1LIFE HEALTHCARE INC 145 6,151 4,794 2U INC 101 5,298 4,209 3D SYSTEMS CORP 230 5,461 9,193 3M CO 1,076 182,991 213,726 8X8 INC 156 2,204 4,331 A O SMITH CORP 401 17,703 28,896 A10 NETWORKS INC 58 350 653 AAON INC 82 3,107 5,132 AARON'S CO INC/THE 43 636 1,376 ABBOTT LABORATORIES 3,285 156,764 380,830 ABBVIE INC 3,463 250,453 390,072 ABERCROMBIE & FITCH CO 88 2,520 4,086 ABIOMED INC 81 6,829 25,281 ABM INDUSTRIES INC 90 2,579 3,992 ACACIA RESEARCH CORP 105 1,779 710 ACADIA HEALTHCARE CO INC 158 8,583 9,915 ACADIA PHARMACEUTICALS INC 194 6,132 4,732 ACADIA REALTY TRUST 47 1,418 1,032 ACCELERATE DIAGNOSTICS INC 80 1,788 645 ACCELERON PHARMA INC 70 2,571 8,784 ACCO BRANDS CORP 187 1,685 1,614 ACCURAY INC 64 483 289 ACI WORLDWIDE INC 166 3,338 6,165 ACTIVISION BLIZZARD INC 1,394 52,457 133,043 ACUITY BRANDS INC 77 13,124 14,401 ACUSHNET HOLDINGS CORP 130 2,487 6,422 ADAPTHEALTH CORP 394 14,628 10,800 ADAPTIVE BIOTECHNOLOGIES CORP 245 11,342 10,011 ADOBE INC 891 82,407 521,805 ADT INC 117 716 1,262 ADTALEM GLOBAL EDUCATION INC 99 4,475 3,528 ADTRAN INC 102 2,202 2,106 ADVANCE AUTO PARTS INC 36 6,442 7,385 ADVANCED DRAINAGE SYSTEMS INC 116 3,153 13,522 ADVANCED ENERGY INDUSTRIES INC 64 1,704 7,213 ADVANCED MICRO DEVICES INC 2,228 43,435 209,276 ADVERUM BIOTECHNOLOGIES INC 439 8,321 1,537 AECOM 283 12,113 17,920 AERIE PHARMACEUTICALS INC 78 2,709 1,249 AERSALE CORP 2,551 30,599 31,785 AES CORP/THE 1,294 17,534 33,735 AFFILIATED
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • Opioid Dependence: Buprenorphine Prolonged- Release Injection (Buvidal)
    Evidence review Opioid dependence: buprenorphine prolonged- release injection (Buvidal) Publication date: February 2019 This evidence review sets out the best available evidence on buprenorphine prolonged-release injection (Buvidal) for treating opioid dependence. It should be read in conjunction with the evidence summary, which gives the key messages. Commissioned by Public Health England. Disclaimer The content of this evidence review was up-to-date in February 2019. See summaries of product characteristics (SPCs), British national formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information. Copyright © NICE 2019. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3246-7 Evidence review: Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (February 2019) 2 of 29 Contents Contents ..................................................................................................................... 3 Background ................................................................................................................ 4 Product overview ........................................................................................................ 4 Mode of action ........................................................................................................ 4 Regulatory status .................................................................................................... 4 Dosing information .................................................................................................
    [Show full text]
  • 【Research Report】The GR Scores 2018
    Nikko Research Review Research Report Aug. 2019 The GR Scores 2018 Institute of Social System Research Megumi Terayama Yasuyuki Sugiura Abstract Nikko Research Center, Inc. has developed the Governance Research Scores (GR scores), which evaluate the strength of corporate governance in Japanese companies. We list the GR Scores of 100 Is major domestic companies by benchmarking their practices against Japan’s Corporate Governance Code as the domestic standard, and the ICGN Global Governance Principles as the global standard. Here, we report the GR Scores 2018 as of December 31, 2017 in sequential form. The overall domestic average score rose 3.1 points to 51.6% from the previous year. Sixty-nine companies had higher domestic scores, and only eight companies had lower scores, compared with the previous year. Disclosing the result of board evaluations, conducting effective board meetings, and setting targets such as earnings in the medium-term management plan seemed to drive this improvement in scores. The overall global average score also rose 1.4 points to 22.3% from the previous year; however, it remains low. While 63 companies had higher global scores, 25 companies had lower scores compared with the previous year. The main reasons for the rise include easing of the requirement of independence for controlled companies by ICGN in their revised principles and a certain number of companies adopting restricted stock for management compensation. By contrast, a tightening of the independence requirement for the audit committee lowered the global scores. Table of Contents 1. Introduction 2. Outline of the GR Scores 2018 2.1 Evaluation method 2.2 Revision of evaluation items from the GR Scores 2017 3.
    [Show full text]
  • Advances in Management of Diabetic Retinopathy Featuring the P
    Advances in Management of Diabetic Retinopathy featuring the P. Kenneth Nase Memorial Lecture (05/22/21 @ 8 a.m. ET) Saturday, May 22, 2021 Online Name of commercial interest/Nature Name of individual Individual's role in activity of relationship Grant / Research Support-Apellis Pharmaceuticals|Grant / Research Support-Genentech|Consultant / Independent Contractor-Apellis Allen Chiang, MD Faculty Pharmaceuticals|Grant / Research Support-Regeneron|Consultant / Independent Contractor-Orbit Biomedical - 03/19/2021 Consultant / Independent Contractor- Michael N Cohen, MD Faculty Allergan|Consultant / Independent Contractor-Keeler, Inc. - 05/04/2021 Consultant / Independent Contractor- Deciphera|Consultant / Independent Contractor-Bausch & Lomb|Consultant / Independent Contractor-Johnson and Johnson|Consultant / Independent Sunir J. Garg, MD Faculty Contractor-Allergan|Grant / Research Support-Regeneron|Grant / Research Support-Apellis|Grant / Research Support-Boehringer Ingelheim - 02/24/2021 Omesh Gupta, MD Faculty Nothing to disclose - 03/21/2021 Advisor / Board Member-IVERIC Bio|Grant / Research Support-IVERIC Bio|Consultant / Independent Contractor-Gyroscope Jason Hsu, MD Faculty Therapeutics|Consultant / Independent Contractor-OccuRx|Grant / Research Support-Genentech|Grant / Research Support-Aldeyra Therapeutics - 03/20/2021 Consultant / Independent Contractor- Allergan|Consultant / Independent M. Ali Khan, MD Faculty Contractor-Apellis Pharmaceuticals|Consultant / Independent Contractor- Genentech|Grant / Research Support- Regeneron
    [Show full text]
  • Amgen Inc. V. Sanofi, No
    No. IN THE Supreme Court of the United States ———— AMGEN INC., AMGEN MANUFACTURING LIMITED, AND AMGEN USA, INC., Petitioners, v. SANOFI, AVENTISUB LLC, REGENERON PHARMACEUTICALS INC., AND SANOFI-AVENTIS U.S., LLC, Respondents. ———— On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit ———— PETITION FOR A WRIT OF CERTIORARI ———— STUART L. WATT JEFFREY A. LAMKEN WENDY A. WHITEFORD Counsel of Record ERICA S. OLSON MICHAEL G. PATTILLO, JR. EMILY C. JOHNSON SARAH J. NEWMAN AMGEN INC. MOLOLAMKEN LLP One Amgen Center Drive The Watergate, Suite 660 Thousand Oaks, CA 91320 600 New Hampshire Ave., NW (805) 447-1000 Washington, D.C. 20037 (202) 556-2000 [email protected] Counsel for Petitioners :,/621(3(635,17,1*&2,1&± ±:$6+,1*721'& QUESTION PRESENTED The 1952 Patent Act requires patents to “contain a written description of the invention, and of the manner and process of making and using it.” 35 U.S.C. §112(a). The “written description” must be “in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same.” Ibid. “The object of the statute is to require the patentee to describe his invention so that others may construct and use it after the expiration of the patent.” Schriber-Schroth Co. v. Cleveland Tr. Co., 305 U.S. 47, 57 (1938). The Federal Circuit has construed §112(a) as impos- ing separate “written description” and “enablement” re- quirements subject to different standards.
    [Show full text]